ID25592A - Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut - Google Patents

Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut

Info

Publication number
ID25592A
ID25592A IDW20001816A ID20001816A ID25592A ID 25592 A ID25592 A ID 25592A ID W20001816 A IDW20001816 A ID W20001816A ID 20001816 A ID20001816 A ID 20001816A ID 25592 A ID25592 A ID 25592A
Authority
ID
Indonesia
Prior art keywords
microparticles
lipofilic
contain drugs
anti gen
formulation consist
Prior art date
Application number
IDW20001816A
Other languages
English (en)
Indonesian (id)
Inventor
Myung-Jin Kim
Sun-Jin Kim
Kyu-Chan Kwon
Joon Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019990001232A external-priority patent/KR100329336B1/ko
Priority claimed from KR1019990059776A external-priority patent/KR100359252B1/ko
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of ID25592A publication Critical patent/ID25592A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IDW20001816A 1999-01-18 2000-01-14 Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut ID25592A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019990001232A KR100329336B1 (ko) 1999-01-18 1999-01-18 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형
KR1019990059776A KR100359252B1 (ko) 1999-12-21 1999-12-21 항원을 포함하는 고체상 미세입자 및 이를 포함하는 제제

Publications (1)

Publication Number Publication Date
ID25592A true ID25592A (id) 2000-10-19

Family

ID=26634599

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001816A ID25592A (id) 1999-01-18 2000-01-14 Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut

Country Status (19)

Country Link
EP (2) EP1071407B1 (pl)
JP (1) JP3802348B2 (pl)
CN (1) CN1142772C (pl)
AR (1) AR043272A1 (pl)
AU (1) AU751200B2 (pl)
BG (1) BG65233B1 (pl)
BR (1) BR0004152A (pl)
CA (1) CA2324403C (pl)
DK (1) DK1071407T3 (pl)
ES (1) ES2505696T3 (pl)
HU (1) HUP0101040A3 (pl)
ID (1) ID25592A (pl)
IL (1) IL138468A0 (pl)
MY (1) MY125541A (pl)
NZ (1) NZ506975A (pl)
PL (1) PL200954B1 (pl)
TR (1) TR200002683T1 (pl)
TW (1) TWI260988B (pl)
WO (1) WO2000041682A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236771B1 (ko) * 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
US6998393B2 (en) * 2000-06-23 2006-02-14 Biopharm Solutions, Inc. Aquespheres, their preparation and uses thereof
WO2003009868A1 (en) * 2001-07-26 2003-02-06 Otago Innovation Limited Antigenic compositions
CA2516339A1 (en) * 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited Dispersing agent for sustained-release preparation
JP4683319B2 (ja) * 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
US7651694B2 (en) * 2004-02-13 2010-01-26 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
WO2005120484A1 (ja) * 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
KR100729954B1 (ko) * 2004-12-01 2007-06-20 주식회사 엘지생명과학 Ｓｅｃ１ 변이 단백질의 제형 및 그것의 제형화 방법
US8932633B2 (en) 2005-08-29 2015-01-13 Biopharm Solutions Inc. Polysaccharide microparticles containing biological agents: their preparation and applications
WO2007076131A2 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
FR2904219B1 (fr) * 2006-07-28 2010-08-13 Flamel Tech Sa Microparticules a base de copolymere amphiphile et de principe(s) actif(s) a liberation modifiee et formulations pharmaceutiques en contenant
CN101618213B (zh) * 2008-07-03 2013-01-23 武汉生物制品研究所有限责任公司 麻疹腮腺炎乙型脑炎联合减毒活疫苗及其制备方法
AU2009302111A1 (en) * 2008-10-08 2010-04-15 Immune Solutions Limited Oral vaccines for producing mucosal immunity
WO2014206857A1 (en) * 2013-06-28 2014-12-31 Universitat Autonoma De Barcelona Oil-in-water formulations of mycobacterium and uses thereof
CN103923881B (zh) * 2013-08-09 2016-04-06 北京科兴生物制品有限公司 甲肝病毒单克隆抗体及其应用
CN112316129B (zh) 2014-04-03 2025-01-28 勃林格殷格翰动物保健美国有限公司 猪流行性腹泻病毒疫苗
GB201716419D0 (en) 2017-10-06 2017-11-22 Univ Central Lancashire Solid composition
KR20220070246A (ko) 2019-09-23 2022-05-30 디디에스 리서치 인크. 침투 증진제를 갖는 지질 소포 조성물
CN112933044A (zh) * 2020-12-17 2021-06-11 太阳雨林（厦门）生物医药有限公司 一种用于恶性肿瘤治疗的载药油制剂及制备方法和应用
CN112961221B (zh) * 2021-02-28 2022-05-17 长春祈健生物制品有限公司 一种水痘-带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
MX2023011157A (es) 2021-03-24 2024-01-25 Glo Pharma Inc Peptidos y metodos para reducir la pigmentacion de la piel.
CN118319983B (zh) * 2024-04-18 2025-10-28 中国疾病预防控制中心病毒病预防控制所 复方sh在制备广谱抗正痘病毒药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059421A (en) * 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
JPH01287041A (ja) 1988-05-13 1989-11-17 Rooman Kogyo:Kk 徐放性製剤
JP2513276B2 (ja) 1988-06-10 1996-07-03 日本電気株式会社 位相同期ル―プ
US5416017A (en) 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
DE69128455T2 (de) * 1990-11-06 1998-06-18 Inst Nacional De Engenharia E Liposomale Mittel sowie Verfahren zu deren Herstellung
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
ATE198547T1 (de) * 1993-11-03 2001-01-15 Isomed Inc Mizelleförmige feinteilige pharmazeutische zusammensetzungen
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
KR100201352B1 (ko) 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
DE69732308T2 (de) * 1996-09-27 2005-06-02 Jagotec Ag Arzneistoffverabreichungssystem mit hyaluronsäure
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
AU2001280934A1 (en) * 2000-07-28 2002-02-13 Alliance Pharmaceutical Corp. Methods and compositions to upregulate, redirect or limit immune responses to bioactive compounds

Also Published As

Publication number Publication date
AU3080500A (en) 2000-08-01
HK1036415A1 (en) 2002-01-04
DK1071407T3 (da) 2014-10-20
HUP0101040A2 (hu) 2001-08-28
ES2505696T3 (es) 2014-10-10
NZ506975A (en) 2004-01-30
JP2002534459A (ja) 2002-10-15
PL342967A1 (en) 2001-07-16
BG65233B1 (bg) 2007-09-28
TR200002683T1 (tr) 2000-12-21
JP3802348B2 (ja) 2006-07-26
BG104742A (en) 2001-07-31
IL138468A0 (en) 2001-10-31
CA2324403A1 (en) 2000-07-20
AR043272A1 (es) 2005-07-27
TWI260988B (en) 2006-09-01
CN1142772C (zh) 2004-03-24
WO2000041682A1 (en) 2000-07-20
EP2481401A1 (en) 2012-08-01
EP1071407A4 (en) 2009-05-20
PL200954B1 (pl) 2009-02-27
EP1071407A1 (en) 2001-01-31
EP1071407B1 (en) 2014-07-23
CN1293568A (zh) 2001-05-02
CA2324403C (en) 2005-12-13
MY125541A (en) 2006-08-31
BR0004152A (pt) 2000-11-21
AU751200B2 (en) 2002-08-08
HUP0101040A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
CY2014003I1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
PT1207867E (pt) Formas de administracao farmaceuticas orais retardadas contendo tramadol
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
PT1221917E (pt) Dispositivo para ministrar medicamentos
EE05123B1 (et) Antiprogestiinsete omadustega ravimite manustamise vahendid
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE602004014283D1 (de) System zur Einführung von mehreren Medizinprodukten
IS5245A (is) Lyfjablanda úr ómeprasól
PT1221918E (pt) Administracao de drogas sub-tenon
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
HUP0400096A2 (hu) Biszfoszfonátok gyógyászati alkalmazása
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20033384D0 (no) Farmasöytisk formulering
EP1547588A4 (en) SOFT CAPSULE PREPARATION
NO20033785D0 (no) Farmasöytisk formulering
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
GB0202633D0 (en) Stabilization of protein preparations
ID25535A (id) Komposisi batangan yang terdiri dari tetesan-tetesan pelunak yang terperangkap terdispersi padanya
NO20044916L (no) Preparater av sulfinylacetamid
EP1502588A4 (en) Light-stabilized soft capsule formulations
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
HUP0600778A2 (en) Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DE60232290D1 (de) Kontrollierte Auflösung von Wirkstoffen